Sara A. Hurvitz, MD, FACP / Miguel Martín, MD, PhD - Integrating Advances in HR+ HER2- Early Breast Cancer: A Focus on Targeted Adjuvant Regimens

Please visit answersincme.com/MHQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss how to optimize the use of oral targeted adjuvant therapy in patients with high-risk, HR+ HER2- early breast cancer. Upon completion of this activity, participants should be better able to: Identify which patients with HR-positive HER2-negative (HR+ HER2-) early breast cancer are at high risk for recurrence; Review the clinical significance of the latest data for targeted adjuvant treatment of HR+ HER2- high-risk early breast cancer; Outline proactive, patient-centered strategies to optimize the care of patients with HR+ HER2- high-risk early breast cancer.

There are no comments yet.

Please log in to write the first comment.